Javier Narváez

Javier Narváez

Auto-generated profile, based on publicly available information

Javier Narváez

Departamento de Salud Pública, Facultad de Medicina, Universidad Nacional de Colombia, Carrera 30 # 45-03, Bogotá, Colombia

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2004 in Annals of Human Biology
Verified
Journal Article
Closed access
JCJorge E Chavarro
Jorge E Chavarro
EVE. Villamor
E. Villamor
JNJ. Narváez
J. Narváez
AHA. Hoyos
A. Hoyos
Age at menarche is an important developmental milestone known to be modified by social and environmental factors. The determinants and potential change over time of age at menarche in Colombia are not well documented. To obtain a current estimate of age at menarche in Colombia and to examine the associations between socio-demographic characteristics and age at menarche. Between 1998 and 2001, we obtained recalled age at menarche, socio-demographic characteristics, and physical activity information in a group of 3206 students at the National University of Colombia who completed a self-administered questionnaire. We examined the cross-sectional associations between mean age at menarche and migratory pattern, parental education, socio-economic status indicators, practice of physical activity, and year of birth using linear regression. Mean age at menarche (+/- SD) was 12.68 +/- 1.31. In a multivariate adjusted regression model, age at menarche was positively associated with family size and the practice of at least 2 daily hours of physical activity, and was inversely related to urbanization level, socio-economic status, and year of birth. Socio-economic status is a strong predictor of menarche in this population. There appears to be a trend towards earlier menarche by year of birth.

26 May 2005 in International Archives of Occupational and Environmental Health
Verified
Journal Article
Closed access
PDF file
AIAlvaro J Idrovo
Alvaro J Idrovo
LSLuz Helena Sanìn
Luz Helena Sanìn
DCDonald Cole
Donald Cole
JCJorge E Chavarro
Jorge E Chavarro
HCHeidy Cáceres
Heidy Cáceres
MRMauricio Restrepo
Mauricio Restrepo

1 May 2010 in Vaccine
Verified
Journal Article
Closed access
FHFernando De la Hoz-Restrepo
Fernando De la Hoz-Restrepo
NANelson Alvis
Nelson Alvis
JNJavier Narváez
Javier Narváez
NCNatalia Cediel
Natalia Cediel
OGOscar Gamboa
Oscar Gamboa
MVMartha Patricia Velandia
Martha Patricia Velandia

1 March 2017 in Vaccine
Verified
Journal Article
Closed access
JNJavier Narváez
Javier Narváez
MOMay Bibiana Osorio
May Bibiana Osorio
CCCarlos Castañeda-Orjuela
Carlos Castañeda-Orjuela
NZNelson Alvis Zakzuk
Nelson Alvis Zakzuk
NCNatalia Cediel
Natalia Cediel
FHFernando De la Hoz-Restrepo
Fernando De la Hoz-Restrepo

1 June 2009 in Revista de Salud Pública
Verified
Journal Article
Closed access
PDF file
FHFernando De la Hoz-Restrepo
Fernando De la Hoz-Restrepo
NANelson Alvis-Guzmán
Nelson Alvis-Guzmán
JNJavier Narváez
Javier Narváez
LCLuz A. Chocontá-Piraquive
Luz A. Chocontá-Piraquive
A study was carried out in Bogota aimed at estimating the burden of disease associated with human papillomavirus infection (HPV) and the potentially avoidable percentage due to using new vaccines. A literature review was combined with analysing surveillance system data and disease cost evaluation. After adjusting for underreporting and misclassification, it was estimated that 322 deaths from cervical cancer occur annually in Bogota (corresponding to 676 new cases). This would cause the loss of 15 years of life for each 1,000 women per year (most occurring amongst women aged 40 to 69). In addition to cervical cancer, there would be around 6,084 cases of high-grade and 22,984 low-grade cervical lesions yearly. The disease's yearly cost would amount to around 7 million dollars. Important weaknesses were found in the clinical management of women suffering from cervical lesions. Strengthening cervical cancer prevention programmes in Bogota would lead to saving a significant number of deaths, cases of cancer and the costs associated with HPV infection. Introducing an anti-HPV vaccine may be considered, but only as part of a more widespread preventative strategy and provided that more affordable prices have been found.

1 September 2017 in Acta Tropica
Verified
Journal Article
Closed access
RBRafael E. Barreto
Rafael E. Barreto
JNJavier Narváez
Javier Narváez
NSNatalia A. Sepúlveda
Natalia A. Sepúlveda
FVFabián C. Velásquez
Fabián C. Velásquez
SDSandra C. Díaz
Sandra C. Díaz
LMLigia I. Moncada
Ligia I. Moncada